Predictors of Postoperative Radiation Following Laser Resection in Early-Stage Glottic Cancer.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2020 Vol.163(6) p. 1218-1225

Silverman DA, Zhan KY, Puram SV, Eskander A, Teknos TN, Rocco JW, Old MO, Kang SY

Abstract

[OBJECTIVE] Guideline recommendations for the treatment of early-stage glottic cancer are limited to single-modality therapy with surgery or radiation alone. We sought to investigate the clinicopathologic and treatment factors associated with the use of postoperative radiation therapy (PORT) following laser excision for patients with T1-T2N0 glottic squamous cell carcinoma (SCC).

[STUDY DESIGN] Retrospective observational study of the National Cancer Database.

[SETTING] National Cancer Database review from 2004 to 2014.

[PATIENTS AND METHODS] A total of 1338 patients with primary cT1-T2N0M0 glottic SCC undergoing primary laser excision were included. Hospitals were divided into quartiles based on yearly volume of laryngeal laser cases performed. Multivariate logistic regression was performed to identify independent predictors of PORT.

[RESULTS] The overall rate of PORT was 30.0%. Predictors of PORT included treatment at lower-volume hospitals (adjusted odds ratio [aOR] for quartiles 2-4, 1.32-4.84), positive margins (aOR, 3.83 [95% CI, 2.54-5.78]), and T2 tumors (aOR, 3.58 [95% CI, 2.24-5.74]). PORT utilization demonstrated a strong inverse correlation with hospital volume. Among top-quartile hospitals, the rate of PORT was 11.2%, while rates of PORT at second-, third-, and fourth-quartile institutions were 19.2%, 32.2%, and 37.4%, respectively.

[CONCLUSIONS] Predictors of PORT in multivariable analysis included treatment at lower-volume facilities, positive margins, and T2 disease. This study highlights the importance of treating early-stage glottic carcinoma at high-volume institutions. In addition, there is a need to reevaluate the use of PORT and reduce the rate of dual-modality therapy for patients with early-stage glottic SCC.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
해부 laryngeal scispacy 1
약물 third- scispacy 1
약물 [OBJECTIVE] Guideline scispacy 1
약물 [aOR] for scispacy 1
약물 [CONCLUSIONS] scispacy 1
질환 Glottic Cancer C0740083
Carcinoma of glottis
scispacy 1
질환 T1-T2N0 glottic squamous cell carcinoma C0280325
Glottic Squamous Cell Carcinoma
scispacy 1
질환 SCC → squamous cell carcinoma C0007137
Squamous cell carcinoma
scispacy 1
질환 Cancer C0006826
Malignant Neoplasms
scispacy 1
질환 T2 tumors C0027651
Neoplasms
scispacy 1
질환 T2 disease C0012634
Disease
scispacy 1
질환 glottic carcinoma C0740083
Carcinoma of glottis
scispacy 1
질환 early-stage glottic SCC scispacy 1
질환 early-stage glottic cancer scispacy 1
질환 glottic SCC scispacy 1
질환 PORT → postoperative radiation therapy scispacy 1
질환 early-stage glottic carcinoma scispacy 1
기타 patients scispacy 1

MeSH Terms

Aged; Combined Modality Therapy; Female; Glottis; Humans; Laryngeal Neoplasms; Laser Therapy; Male; Margins of Excision; Neoplasm Staging; Retrospective Studies